CN Patent

CN120641101A — 用于治疗高蛋白尿慢性肾病的齐泊腾坦和达格列净的组合

Assigned to AstraZeneca AB · Expires 2025-09-12 · 1y expired

What this patent protects

公开了用于通过使用齐泊腾坦和达格列净的固定剂量组合来治疗患者的高蛋白尿慢性肾病和/或与其相关联的至少一种疾病、病症或病况的方法。

USPTO Abstract

公开了用于通过使用齐泊腾坦和达格列净的固定剂量组合来治疗患者的高蛋白尿慢性肾病和/或与其相关联的至少一种疾病、病症或病况的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN120641101A
Jurisdiction
CN
Classification
—
Expires
2025-09-12
Drug substance claim
No
Drug product claim
No
Assignee
AstraZeneca AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.